536 related articles for article (PubMed ID: 33322746)
21. Whole Genome Sequencing Prioritizes
Srivastava A; Giangiobbe S; Skopelitou D; Miao B; Paramasivam N; Diquigiovanni C; Bonora E; Hemminki K; Försti A; Bandapalli OR
Front Endocrinol (Lausanne); 2021; 12():600682. PubMed ID: 33692755
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.
Schwartz CJ; Khorsandi N; Blanco A; Mukhtar RA; Chen YY; Krings G
Breast Cancer Res Treat; 2024 Feb; 204(1):171-179. PubMed ID: 38091153
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.
Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L
BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081
[TBL] [Abstract][Full Text] [Related]
24. A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk.
Wang N; Ding H; Liu C; Li X; Wei L; Yu J; Liu M; Ying M; Gao W; Jiang H; Wang Y
Oncogene; 2015 Oct; 34(40):5198-205. PubMed ID: 25619829
[TBL] [Abstract][Full Text] [Related]
25. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
[TBL] [Abstract][Full Text] [Related]
26. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
27. Cancer Susceptibility Mutations in Patients With Urothelial Malignancies.
Carlo MI; Ravichandran V; Srinavasan P; Bandlamudi C; Kemel Y; Ceyhan-Birsoy O; Mukherjee S; Mandelker D; Chaim J; Knezevic A; Rana S; Fnu Z; Breen K; Arnold AG; Khurram A; Tkachuk K; Cipolla CK; Regazzi A; Hakimi AA; Al-Ahmadie H; Dalbagni G; Cadoo KA; Walsh MF; Teo MY; Funt SA; Coleman JA; Bochner BH; Iyer G; Solit DB; Stadler ZK; Zhang L; Rosenberg JE; Taylor BS; Robson ME; Berger MF; Vijai J; Bajorin DF; Offit K
J Clin Oncol; 2020 Feb; 38(5):406-414. PubMed ID: 31794323
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing.
Slavin TP; Coffee B; Bernhisel R; Logan J; Cox HC; Marcucci G; Weitzel J; Neuhausen SL; Mancini-DiNardo D
Cancer Genet; 2019 Jun; 235-236():31-38. PubMed ID: 31056428
[TBL] [Abstract][Full Text] [Related]
29. Nuclear expression of Ku70/80 is associated with CHEK2 germline mutations in breast cancer.
Jakub R; Filip M; Daniel B; Jolanta H; Tomasz H; Cezary C; Jan L; Wenancjusz D; Domagała P
Pol J Pathol; 2023; 74(2):75-81. PubMed ID: 37728466
[TBL] [Abstract][Full Text] [Related]
30. High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.
Rainville I; Hatcher S; Rosenthal E; Larson K; Bernhisel R; Meek S; Gorringe H; Mundt E; Manley S
Breast Cancer Res Treat; 2020 Apr; 180(2):503-509. PubMed ID: 31993860
[TBL] [Abstract][Full Text] [Related]
31. CHEK2 mutations and the risk of papillary thyroid cancer.
Siołek M; Cybulski C; Gąsior-Perczak D; Kowalik A; Kozak-Klonowska B; Kowalska A; Chłopek M; Kluźniak W; Wokołorczyk D; Pałyga I; Walczyk A; Lizis-Kolus K; Sun P; Lubiński J; Narod SA; Góźdż S
Int J Cancer; 2015 Aug; 137(3):548-52. PubMed ID: 25583358
[TBL] [Abstract][Full Text] [Related]
32. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
33. Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
Hanson H; Astiazaran-Symonds E; Amendola LM; Balmaña J; Foulkes WD; James P; Klugman S; Ngeow J; Schmutzler R; Voian N; Wick MJ; Pal T; Tischkowitz M; Stewart DR;
Genet Med; 2023 Oct; 25(10):100870. PubMed ID: 37490054
[TBL] [Abstract][Full Text] [Related]
34. Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families.
Dominguez-Valentin M; Nakken S; Tubeuf H; Vodak D; Ekstrøm PO; Nissen AM; Morak M; Holinski-Feder E; Martins A; Møller P; Hovig E
Fam Cancer; 2018 Jan; 17(1):141-153. PubMed ID: 28608266
[TBL] [Abstract][Full Text] [Related]
35. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
Näslund-Koch C; Nordestgaard BG; Bojesen SE
J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
[TBL] [Abstract][Full Text] [Related]
36. Homologous Recombination Deficiencies and Hereditary Tumors.
Yamamoto H; Hirasawa A
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008774
[TBL] [Abstract][Full Text] [Related]
37. A novel CHEK2 variant identified by next generation sequencing in an Indian family with hereditary breast cancer syndrome.
Bhai P; Saxena R; Kulshrestha S; Verma IC
Cancer Genet; 2019 Jun; 235-236():13-17. PubMed ID: 31296309
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers.
Toss A; Tenedini E; Piombino C; Venturelli M; Marchi I; Gasparini E; Barbieri E; Razzaboni E; Domati F; Caggia F; Grandi G; Combi F; Tazzioli G; Dominici M; Tagliafico E; Cortesi L
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33919281
[TBL] [Abstract][Full Text] [Related]
39. CHEK2 Germ Line Mutations are Lacking among Familial and Sporadic Breast Cancer Patients in Rwanda.
Habyarimana T; Attaleb M; Mugenzi P; Mazarati JB; Bakri Y; El Mzibri M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):375-379. PubMed ID: 29479983
[TBL] [Abstract][Full Text] [Related]
40. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
